Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up – Should You Buy?

Fresenius SE & Co. (OTCMKTS:FSNUY) shares gapped up before the market opened on Monday. The stock had previously closed at $13.0420, but opened at $13.67. Fresenius SE & Co. shares last traded at $13.6810, with a volume of 485 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Finally, Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday. Three analysts have rated the stock with a Buy rating. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Fresenius SE & Co. Trading Up 2.6%

The company has a market cap of $30.87 billion, a PE ratio of 17.34 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.28 and a quick ratio of 0.97. The company has a 50-day moving average of $12.89 and a 200 day moving average of $12.87.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%. The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Analysts predict that Fresenius SE & Co. will post 1.04 earnings per share for the current year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.